1

TITLE: A genomic variant of *ALPK2* is associated with increased liver fibrosis risk in HIV/HCV coinfected women

Author Names and Affiliations: Alec T. McIntosh,¹ Renhuizi Wei,¹ Jaeil Ahn,² Brad E. Aouizerat,³ Seble G. Kassaye,⁴ Michael H. Augenbraun,⁵ Jennifer C. Price,⁶ Audrey L. French,⁷ Stephen J. Gange,⁸ Kathryn M. Anastos,⁹ and Radoslav Goldman^{1,10,11,*}

¹Department of Oncology, Georgetown University, Washington, DC

²Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC

³Bluestone Center for Clinical Research, College of Dentistry, New York University, New York, NY

⁴Department of Infectious Diseases, Georgetown University Medical Center, Washington, DC

⁵Department of Medicine, Division of Infectious Diseases, State University of New York, Downstate Medical Center, Brooklyn, NY

⁶Department of Medicine, Division of Liver Diseases, University of California San Francisco, San Francisco, CA

⁷Department of Internal Medicine, Division of Infectious Disease, Stroger Hospital of Cook County, Chicago, IL

⁸Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

⁹Departments of Medicine and Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY

¹⁰Department of Biochemistry and Molecular & Cell Biology, Georgetown University Medical Center, Washington, DC

¹¹Clinical Translational Glycoscience Research Center, Georgetown University Medical Center, Washington, DC

***Corresponding Author Information:** Radoslav Goldman, Georgetown University, Department of Oncology, NRB E207, 3970 Reservoir Road NW, Washington, DC 20057. Phone: 202-687-9868; E-mail: rg26@georgetown.edu

2

1 ABSTRACT

2 HIV coinfection is associated with more rapid liver fibrosis progression in hepatitis C 3 (HCV) infection. Recently, much work has been done to improve outcomes of liver 4 disease and to identify targets for pharmacological intervention in coinfected patients. In 5 this study, we analyzed clinical data of 1,858 participants from the Women's 6 Interagency HIV Study (WIHS) to characterize risk factors associated with changes in 7 the APRI and FIB-4 surrogate measurements for advanced fibrosis. We assessed 887 8 non-synonymous single nucleotide variants (nsSNV) in a subset of 661 coinfected 9 participants for genetic associations with changes in liver fibrosis risk. The variants utilized produced amino acid substitutions that either altered an N-linked glycosylation 10 11 (NxS/T) sequen or mapped to a gene related to glycosylation processes. Seven variants 12 were associated with an increased likelihood of liver fibrosis. The most common variant, 13 ALPK2 rs3809973, was associated with liver fibrosis in HIV/HCV coinfected patients; 14 individuals homozygous for the rare C allele displayed elevated APRI (0.61, 95% CI, 15 0.334 to 0.875) and FIB-4 (0.74, 95% CI, 0.336 to 1.144) relative to those coinfected 16 women without the variant. Although warranting replication, ALPK2 rs3809973 may 17 show utility to detect individuals at increased risk for liver disease progression.

18

19 **INTRODUCTION**

The emergence of highly active antiretroviral therapy has transitioned the once acutely fatal human immunodeficiency virus (HIV) infection to a chronic disease. However, the longer survival of persons living with HIV infection presents a new set of morbidities and increased risk for mortality [1-3]. Due to common modes of transmission, those infected

It is made available under a CC-BY 4.0 International license .

3

24 with HIV are at higher risk of contracting hepatitis C virus (HCV). Accelerated progression of liver disease in HIV/HCV coinfected patients compared to those with 25 HCV monoinfection is well documented and liver disease has become a leading cause 26 27 of non-AIDS related death in coinfected individuals [4,5]. The pathogenesis of liver 28 disease in coinfected individuals is multifactorial [6]. Despite substantial progress in 29 identifying risk factors for liver disease progression in coinfected persons, our 30 understanding of risk factors remains incomplete, with genomic factors among those 31 that remain ill-defined. Even with the emergence of direct-acting HCV antivirals, the 32 ability of these agents to regress fibrosis upon HCV clearance remains unclear [7] and the cost of treatment is often inaccessible to at-risk populations [8]. Taken together, 33 34 these considerations document that liver fibrosis remains a challenge in coinfected and 35 HCV monoinfected patients. In this study, we examined the impact of non-synonymous 36 single nucleotide variants (nsSNV) affecting N-glycosylation both directly at the NxS/T 37 sequons of proteins and indirectly through the enzymes and lectins of glycosylation-38 related pathways.

39

Glycosylation is one of the most common and structurally diverse protein modifications and affects protein synthesis, structure, and function [9]. Glycosylation enzymes or the glycoproteins they produce are involved in immune surveillance and host-pathogen interactions [10,11] as well as in the progression of viral liver disease [12]. To elucidate the impacts of glycosylation on the pathogenesis of fibrosis in HIV/HCV coinfected patients, we focused on nsSNV affecting the NxS/T sequons required for the attachment of N-glycans to proteins and thus the potential to change the number of

4

47 glycans on the protein surface [13,14]. The Women's Interagency HIV Study (WIHS) is 48 a longitudinal natural history study of HIV infection that features a sufficient number of 49 HIV/HCV coinfected participants and biomarkers of liver disease to evaluate the impact 50 of risk factors for liver disease progression [15], including genetic risk factors [16-18]. 51 Given its longitudinal cohort design, the Fibrosis-4 Index (FIB-4)[19] and the AST to 52 Platelet Ratio Index (APRI)[20] were collected in the WIHS cohort as noninvasive 53 surrogate measures of hepatic fibrosis. These measures were used in lieu of serial 54 tissue biopsy as the means with which to evaluate genetic risk factors in HIV/HCV 55 coinfection [21]. A set of 887 nsSNV were extracted from a genome-wide association study performed in the WIHS cohort. Of these, 278 nsSNV produce an amino acid 56 57 substitution that alters the potential glycosylation of target proteins by altering the 58 number of N-glycans decorating a protein, which we analyzed in relation to surrogate 59 biomarkers of liver fibrosis. Given that previous work demonstrated that genetic 60 variation in glycosylation-related enzymes and lectins can alter kinetics and binding 61 affinities respectively, the remaining 609 of 887 nsSNV were glycosylation-related proteins evaluated in relation to surrogate biomarkers of liver fibrosis in coinfected 62 63 participants [22,23].

64

65 **METHODS**

66 Study Population

The WIHS is a multicenter prospective study of the natural history of HIV infection
among women with or at risk for HIV-infection in the United States. Established in 1994,
a total of 4,982 women (3,677 HIV-seropositive) have been enrolled. At semi-annual

5

70 visits, participants completed socio-demographic and medical guestionnaires, laboratory 71 testing, and a limited physical examination. Data included in this analysis include age, 72 race and ethnicity, continuous clinical measures of liver fibrosis (APRI and FIB-4). 73 plasma HIV RNA viral titer, HCV infection status (at all visits), and HCV viral titer (at 74 baseline only) [24]. HCV status was defined as "positive" when participants had both 75 positive HCV antibody and detectable HCV RNA at their baseline visit. Those that were 76 defined as "negative" had no detectable HCV antibody upon testing. Self-reported race 77 and ethnicity was used to define four groups: "White" (non-Hispanic), "African American" 78 (non-Hispanic), "Hispanic", or "Other". In addition to self-reported race and ethnicity, 79 genomic estimates of ancestry were derived using principle component analysis of 80 ancestry informative genetic markers [25].

81

82 Genotyping

Genotype data in WIHS was generated from genomic DNA from peripheral blood 83 84 mononuclear cells using the Infinium Omni2.5 BeadChip (Illumina, San Diego, CA, 85 USA) [24]. Of the 10,141 genes (602 glycogene + 9,539 NxS/T-containing genes) 86 known to exist in the human genome, data on 1,029 nsSNVs (698 glycogene + 331 87 NxS/T) spanning 660 genes (349 glycogene + 311 NxS/T) from 2,120 WIHS 88 participants were available for analysis [13]. Of these 2,120 women, 262 participants 89 were either HCV antibody positive in the absence of detectable HCV RNA (N=156) or 90 HCV serostatus was never assessed at baseline (N=106) and therefore excluded (Supplemental Figure 1). Of the 331 NxS/T nsSNVs, 44 were mono-allelic (non-91 92 polymorphic) and therefore excluded. Among the 287 nsSNVs that remained, missing

6

93	genotypes across 1,858 patients were imputed with the most common genotype for
94	each nsSNVs (mean participants imputed per nsSNV \pm SD= 5 \pm 6.04). Of the 698
95	glycogene nsSNVs, 75 were monomorphic and excluded. Among the 623 nsSNVs that
96	remained, missing genotypes across 1,858 patients were imputed with the most
97	common genotype for each nsSNV (mean participants imputed per nsSNV±SD=
98	5±6.21). A minor allele frequency (MAF) threshold ≥0.001 (≥0.1%) was applied using
99	the MAFs of the coinfected population (N=661) to further isolate SNVs sufficiently
100	frequent to allow for statistical analysis. Using this method, an additional 9 NxS/T and
101	14 glycogenes were eliminated from analysis. After applying all exclusion criteria,
102	clinical and genotype (887 glycogene [609 nsSNV, 278 NxS/T nsSNV] spanning 564
103	genes) data were available for 1,858 women (Supplemental Figure 1). The nsSNV
104	reference sequence identifiers (rsID), major (or common) and minor (or rare) alleles,
105	and MAF across serotypes are provided as supplementary tables for the NxS/T
106	(Supplemental Table 1) and glycogene (Supplemental Table 2) nsSNVs utilized in our
107	analysis.

108

109

Serologic Markers of Fibrosis

Fibrosis-4 Index (FIB-4) and the AST to Platelet Ratio Index (APRI) were used as measures of hepatic fibrosis as described in previous literature [21]. For the FIB-4 index, scores <1.45 and >3.25 indicate a high negative and a high positive predictive value for advanced fibrosis respectively [19]. For APRI, scores <0.5 have a high negative predictive value for liver disease while scores >0.7 and >2 indicate a high positive predictive value for moderate and severe hepatic fibrosis respectively [20].

7

116 Genetic polymorphisms were independently analyzed against each continuous

surrogate index (i.e., APRI, FIB-4) at baseline to identify variants with stronger

associations that would manifest across both current clinical diagnostic resources.

119

120 Statistical Analysis

121 For descriptive summaries, continuous variables were summarized using means and 122 standard deviations while categorical variables were summarized using frequency 123 counts and percentages. HIV and HCV RNA status were categorized into 4 serostatus 124 groups: both HIV/HCV noninfected, HIV monoinfected, HCV monoinfected, and HIV/HCV coinfected. Distributions of APRI, FIB-4, and HIV RNA viral load among the 125 126 four serostatus groups were summarized using descriptive statistics and were 127 compared using chi-square analyses or one-way Analysis of Variance (ANOVA). APRI 128 and FIB-4 scores used for analysis were obtained at baseline visits (pre-2003) at a time 129 prior to the broad use of HCV therapy. For each variant from the 278 NxS/T and 609 glycogene nsSNV that met inclusion criteria, a separate multiple variable linear 130 131 regression model was constructed for the HIV/HCV coinfected patient population for 132 continuous APRI and FIB-4 outcomes. Explanatory variables included each variant, 133 age, race and ethnicity, HIV viral load, and HCV viral load. Model results were 134 indistinguishable when adjusted for HCV viral load or HCV status. Genomic estimates of 135 racial and ethnicity were estimated using principle component analysis of 185 ancestry 136 informative markers (SNV) selected to differentiate major racial and ethnic groups in the cohort (i.e., European, African, Hispanic)[25]. The first three principle components (PC1, 137 PC2, PC3) were utilized to adjust for genomic estimates of race and ethnicity in the 138

8

139	aforementioned linear regression models. HIV and HCV viral load were normalized
140	using $log_2(x+1)$ transformation. The false discovery rate (FDR) was used to account for
141	multiple testing (i.e., 887 linear regression each for FIB-4 and APRI). All reported p-
142	values are two-sided, and SNV associations with FDR<0.05 were considered
143	statistically significant. To investigate whether the impact of SNV varies across the four
144	serogroups, we examined SNV*serostatus interactions and computed 95% confidence
145	intervals for each SNV genotype*serostatus configuration. Statistical analyses were
146	performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 3.3 (R
147	Core Team, Vienna, Austria).
148	
149	RESULTS
150	Of the 75% of women who were HIV seropositive (1386 of 1858), 52% (n=725) were
151	HIV monoinfected and 48% (n=661) were HIV/HCV coinfected (Table 1).
152	The remaining 25% of women (N=472) were HCV/HIV noninfected and 22% (N=104)
153	were HCV monoinfected. The proportion of non-Hispanic African-Americans differed
154	significantly between the four serogroups (P<0.001) (Table 1). Post-hoc contrasts
155	indicate that, in comparison to non-Hispanic African Americans, Hispanics were less
156	likely (OR=0.66 [95% CI, 0.499 to 0.881], <i>P</i> _{FDR} =0.03) and non-Hispanic Whites were
157	more likely (OR=1.82 [95% CI, 1.272 to 2.609], P _{FDR} =0.006) to be in the coinfected
158	serogroup as compared to the HIV monoinfected group. HCV-infected women were
159	older on average (P<0.001) than those not infected with the virus (Table 1). Post-hoc
160	contrasts indicate that in comparison to the noninfected serogroup, older subjects were
161	more likely to be monoinfected with HIV (OR=1.08 [95% CI, 1.059 to 1.100], PFDR

Variable	Noninfected	Monoinfected	Monoinfected	Coinfected	
	HIV-/HCV-	HIV+/HCV-	HIV ⁻ /HCV ⁺	HIV+/HCV+	
Levels	N=368	N=725	N=104	N=661	Р
Age at BL, mean± SD	29.6 ± 8.0	33.2 ± 7.4	39.2 ± 7.2	39.8 ± 6.2	<0.0001
HIV load, mean± SD†	0	11.3 ± 4.4	0	14.0 ± 3.8	<0.0001
HCV load, mean± SD †	0	0	19.1 ± 3.3	20.5 ± 2.8	<0.0001
Race, N(%)					
Non-Hispanic White	47 (12.8)	69 (9.5)	13 (12.5)	111 (16.8)	<0.0001
Non-Hispanic A-A	205 (55.7)	400 (55.2)	63 (60.6)	416 (62.9)	
Hispanic	101 (27.5)	227 (31.3)	23 (22.1)	123 (18.6)	
Other	15 (4.1)	29 (4.0)	5 (4.8)	11 (1.7)	
APRI, N(%)					
<0.5	367 (99.7)	633 (87.3)	64 (61.5)	267 (40.4)	<0.0001
0.5-0.7	0 (0.0)	39 (5.4)	13 (12.5)	135 (20.4)	
>0.7	1 (0.3)	53 (7.3)	27 (26.0)	259 (39.2)	
FIB-4, N(%)					
<1.45	366 (99.5)	657 (90.6)	79 (76.0)	336 (50.8)	<0.0001
1.45-3.25	2 (0.5)	59 (8.1)	20 (19.2)	255 (38.6)	
>3.25	0 (0.0)	9 (1.2)	5 (4.8)	70 (10.6)	

Table 1. Baseline population characteristics of patients by serostatus

Percentages based off columns.

[†]Viral loads are log₂ transformed (copies/mL)

Abbreviations: BL, Baseline; A-A, African-American.

162 <0.001), monoinfected with HCV (OR=1.21 [95% CI, 1.172, to 1.252], *P*_{FDR} <0.001) or

163 coinfected (OR=1.22 [95% CI, 1.197 to 1.252], *P*_{FDR} < 0.001). Distribution of the APRI

and FIB-4 fibrotic indexes, stratified by their clinically relevant cutoffs, also differed

between the groups (*P*<0.001) (Table 1). Six pairwise comparisons of mean liver scores

were performed between designated serogroups for each fibrosis metric (Figure 1). On

167 average, coinfected participants had higher APRI and FIB-4 measures when compared

- to the HCV monoinfected population (APRI, 0.36, 95% CI, 0.064 to 0.651; FIB-4, 0.78,
- 169 95% CI, 0.375 to 1.184) and the HIV monoinfected population (APRI, 0.64, 95% CI,
- 170 0.487 to 0.786; FIB-4, 1.19, 95% CI, 0.984 to 1.397) (Figure 1). All other comparisons
- 171 between serogroups were found to be statistically significant (95% confidence interval)
- 172 except the mean APRI scores for noninfected vs. HIV monoinfected (-0.15, 95% CI, -
- 173 0.325 to 0.031) and HIV monoinfected vs. HCV monoinfected (-0.28, 95% CI, -0.571 to
- 174 0.012) which follow the expected trend but do not achieve statistical significance (Figure
- 175 1).




Figure 1. Mean liver fibrosis scores for each viral serotype. The mean APRI and FIB-4 scores at baseline visit + SD are shown for 1,858 women stratified by definitive viral serostatus. The number of patients (n) for each viral serostatus are indicated in Table 1. Pairwise comparisons of liver outcomes were performed for all viral-serotype group-comparisons within each liver metric. Only those comparisons not significant (*ns*) were labeled as such.

176 Utilizing the larger cohort for race and age adjustment helped to ensure that we had the 177 population size to account for the impact of these variables on liver fibrosis. Whereas 178 the first principle component of the PCA of genomic markers of ancestry (PC1) 179 appeared to adequately differentiate African-Americans (non-Hispanic), Hispanics, and 180 Whites (non-Hispanic) (Figure 2A), we took a conservative approach and included the 181 first three principle components (PC1, PC2, PC3). Although adjusting for race/ethnicity 182 using self-report identified the same genetic associations, we opted to employ the 3 183 PCs to better account for confounding that can occur with self-reported race and 184 ethnicity. For example, many participants self-reporting as "Hispanic" or "Other" in the coinfected subgroup present with a genetic background more consistent with the 185 186 African-American (non-Hispanic) and White (non-Hispanic) clusters (Figure 2B).




Figure 2. Genomic Estimates of Race/Ethnicity using Principle Component Analysis. The 1,858 WIHS participants utilized in this study were stratified using 185 ancestral SNV markers from across the genome. PC1 and PC2 are depicted above. Genomic estimates of race and ethnicity were compared to reported race and ethnicity (A) and the distribution of HIV/HCV coinfected participants of focus are displayed (B).

It is made available under a CC-BY 4.0 International license .

187 After adjustment for multiple testing, seven nsSNV mapping to separate genes met the

188 *a priori* criterion of *P*_{FDR} <0.05 for at least one of the biomarkers of liver fibrosis (Table

- 189 2). Of these, only rs52828316 (MAN2A2) was significant by P_{FDR} for both indices. For all
- 190 nsSNV, two copies of the minor allele (i.e., minor allele homozygotes) was associated
- 191 with increases in APRI and/or FIB-4 (Table 2). Because it was the only variant
- 192 sufficiently frequent to result in all three genotypic groups (i.e., major allele

Model Fit (N	l= 66 ′	I)	SNV + Age + PC1-3 + HIV Load + HCV Load [†]						Study
Outcome	-		APRI			FIB-4			Sample
SNV	Alle	les (N)	Estimate	Ρ	P fdr	Estimate	Р	P fdr	MAF
rs3809973	CC	(154)	0.61	<0.01	<0.01	0.74	<0.01	0.08	0.48
ALPK2	AC	(321)	0.10	0.39		0.15	0.40		
(K829N) [‡]	AA	(186)	0			0			
rs17035120	TT	(4)	2.00	<0.01	0.42	3.77	<0.01	0.05	0.07
GLT8D2	TC	(81)	-0.03	0.84		0.16	0.48		
(A37T) [‡]	CC	(576)	0			0			
rs1800450	AA	(6)	1.52	<0.01	0.15	3.28	<0.01	0.01	0.06
MBL2	AG	(66)	-0.32	0.06		-0.42	0.10		
(G54D)	GG	(589)	0			0			
rs77452813	TT	(2)	3.40	<0.01	0.08	5.90	<0.01	0.01	0.04
MCOLN2	TC	(50)	-0.13	0.50		-0.16	0.58		
(V20I)	CC	(609)	0			0			
rs52828316	AA	(2)	7.55	<0.01	<0.01	6.43	<0.01	<0.01	0.03
MAN2A2	AG	(42)	-0.24	0.24		-0.30	0.33		
(R1039H)	GG	(617)	0			0			
rs2228015	TC	(20)	1.02	<0.01	0.08	1.75	<0.01	0.01	0.02
CCR7	TT	(641)	0			0			
(M7V)									
rs1800472	TC	(13)	1.77	<0.01	<0.01	1.26	0.02	0.66	0.01
TGFB1	CC	(648)	0			0			
(T263I)									

 Table 2. Baseline screen of multiple linear regression models

Bold Indicates Significant P Values.

[†] Multiple Linear Regression of each SNV adjusted for Age, Race (PC1-PC3), HIV and HCV Load.

Single Letter Amino Acid Abbreviation and Position of Resulting Substitution.

[‡]Potential Gain or Loss of an NxS/T Caused by Substitution.

Abbreviations: PC, Principle Component; NxS/T, N-linked Glycosylation Sequon; SNV, Single Nucleotide Variant; MAF, Minor Allele Frequency, FDR, False Discovery Rate.

It is made available under a CC-BY 4.0 International license .

13

193	homozygotes, heterozygotes, minor allele homozygotes), ALPK2 rs3809973 was
194	evaluated further in relation to hepatic fibrosis among the four viral serogroups.

195	In order to see if the ALPK2 variant's tentative association with increased liver fibrosis in
196	coinfected women was preferentially impacted by the effects of either virus, we
197	analyzed each genotype of the ALPK2 variant across all viral serostatuses utilized in the
198	cohort. For the ALPK2 rs3809973, HIV/HCV coinfected participants who were
199	homozygous for the minor allele had significantly higher mean APRI and FIB-4 scores
200	relative to the coinfected participants homozygous for the major allele (APRI, 0.61, 95%
201	CI, 0.334 to 0.875; FIB-4, 0.74, 95% CI, 0.336 to 1.144) and compared to those HCV
202	monoinfected participants homozygous for the minor allele (APRI, 0.79, 95% CI, 0.370
203	to 1.200; FIB-4, 1.24, 95% CI, 0.820 to 1.650) (Figure 3A,3B). Evaluation of the
204	association of ALPK2 rs3809973 with APRI and FIB-4 by racial and ethnic group (i.e.,
205	non-Hispanic African-American, non-Hispanic Caucasian, Hispanic)
206	revealed similar patterns of association with one exception in non-Hispanic African-
207	American where no difference by genotypic group was observed with FIB-4 (data not
208	shown). The heterozygotes of coinfected individuals displayed no significant increases
209	in APRI or FIB-4 relative to the coinfected major allele homozygotes (APRI, 0.10, 95%
210	CI, -0.128 to 0.332; FIB-4, 0.15, 95% CI, -0.195 to 0.492). These coinfected population
211	findings for the ALPK2 nsSNV (rs3809973) are against a background of similar CD4 ⁺ T-
212	cell percentage, measured relative to other leukocyte types, and detectable HIV viral
213	loads at baseline (Figure 3C,3D). HIV monoinfected participants homozygous for the
214	minor allele displayed significantly increased FIB-4 (0.45, 95% CI, 0.028 to 0.879)




Figure 3. rs3809973 (ALPK2) impact on APRI and FIB-4 Outcomes. Mean baseline APRI (A) and FIB-4 (B) score with 95% confidence interval shown for the allele pairs of each serotype (Total N=1,858). The number of samples representing each genotype for the respective serogroups is displayed as follows: homozygous for the major allele (green), heterozygous (orange), and homozygous for the minor allele (blue). Comparisons were shown, for reference, relative to the major allele homozygote of the noninfected serogroup. ANOVA was used to compare relative CD4⁺ T-cell percentages (C) or HIV/HCV viral loads (D) between the genotypes of each serogroup. No significant differences are denoted by *ns.* Asterisks indicate two-sided P-values below 0.05 (*) and 0.01 (**) respectively.

It is made available under a CC-BY 4.0 International license .

scores relative to noninfected participants homozygous for the minor allele, but the
finding was not significant for the same comparison using APRI (0.00, 95% CI, -0.422 to
0.429) (Figure 3A, 3B). For the HIV monoinfected genotype, a slight significant
difference in the CD4⁺ T-cell percentage (*P*=0.007) accompanied this FIB-4 finding.
Impacts of variant *ALPK2* allele burden between genotypes in the noninfected and HCV
monoinfected serogroups were unremarkable (Figure 3A, 3B).

221 **DISCUSSION**

222 This study identified several novel genetic associations among glycogenes and biomarkers of liver fibrosis. Average liver fibrosis scores in the coinfected serogroup 223 224 analyzed at baseline were significantly higher than that of either HIV or HCV 225 monoinfected participants as shown in Figure 1, recapitulating the fibrotic trends 226 described in the literature for coinfected populations [6,26]. Of the 887 nsSNV assessed that either directly (nsSNV affecting NxS/T sequons) or indirectly (nsSNV in 227 228 glycosylation or lectin genes) alter glycosylation pathways or products, we found seven 229 nsSNV that were associated with an increased risk of hepatic fibrosis among the 230 HIV/HCV coinfected population. We observed higher APRI and FIB-4 values (indicative 231 of greater fibrosis) in coinfected participants homozygous for the ALPK2 rs3809973 232 minor allele when compared with participants homozygous for the ALPK2 rs3809973 233 major allele irrespective of HIV and HCV viral load. As elevations in these viral titers 234 have been correlated with increased liver injury [27], our findings suggest that the 235 genetic risk of hepatic fibrosis among coinfected individuals carrying the ALPK2 236 rs3809973 risk allele is not confounded by viral titers. The lack of association in

16

237	coinfected participants between the ALPK2 variant heterozygote and increased liver
238	fibrosis suggested the need for variant homozygosity for the detrimental impacts of the
239	variant to manifest in the coinfected and conforms with a recessive mode of inheritance.
240	As shown in Figure 3, among HIV monoinfected participants, the relative CD4 ⁺ T-cell
241	percentage among leukocytes was inversely associated with FIB-4. Furthermore,
242	coinfected participants that were homozygous for the minor allele were significantly
243	increased in terms of fibrosis risk when compared to HCV monoinfected participants of
244	the same genotype; suggesting a need for general HIV-associated immunosuppression
245	to produce the detrimental fibrosis risk increase. Our comparisons of ALPK2 rs3809973
246	among serogroups at baseline therefore leads us to speculate that the risk allele's
247	impact on liver fibrosis is reliant on both HCV-mediated liver damage and its
248	perpetuation by HIV-mediated immunosuppression.

249 The ALPK2 gene and rs3809973 have not been linked to a pathological liver phenotype 250 to date. Although the association of ALPK2 rs3809973 with fibrosis in the setting of 251 HIV/HCV coinfection warrants replication, some circumstantial evidence suggests a 252 potential role for ALPK2 in risk for viral hepatic fibrosis. Hepatic Stellate cells (HSC) 253 lining the perisinusoidal space of the liver are the fibrogenic cell type responsible for 254 extracellular matrix deposition and subsequent fibrosis in the setting of hepatic 255 inflammation. Although this fibrogenic response is designed to protect against liver 256 injury and typically reverses after the hepatic insult subsides, progressive inflammation 257 and the chronic activation of HSCs can lead to cirrhosis and an increased risk of 258 developing hepatocellular carcinoma [28,29]. Signaling molecules and pathways

17

259 involved in HSC activation have been described, but most notable is the expression of 260 toll-like receptors on HSCs enables their activation upon exposure to structurally 261 conserved microbial-derived products such as lipopolysaccharide [30]. Although 262 incompletely characterized, the ALPK2 protein was first identified in cardiomyocytes as 263 an integral regulator of heart development [31]. However, most studies of ALPK2 have 264 focused on the pathological processes of the gastrointestinal tract. ALPK2 is associated 265 with luminal apoptosis in colorectal cancer cell lines [32]. Luminal shedding is a 266 phenomenon of the enteric innate immune system designed to maintain the function of 267 the gut barrier by preventing the invasion of virulent microbes into systemic circulation. 268 The increased apoptosis of enterocytes in the absence of their concomitant 269 replacement can yield an increasingly permeable intestinal membrane that leaves the 270 host vulnerable to augmented translocation of microbial products [33]. Since increased 271 microbial translocation is a hallmark of HIV infection and lipopolysaccharide activates 272 HSCs [34], any augmentation of this translocation process would exacerbate liver 273 fibrosis in the context of existing hepatitis. In addition, a genome-wide association study 274 of inflammatory bowel disease, a condition in which pathological epithelial shedding is 275 observed, found the mRNA of ALPK2 to be up-regulated in inflamed mucosa compared 276 to control samples [35]. Therefore, we speculate that ALPK2 rs3809973 could enhance 277 liver fibrosis by interfering with enteric immunity. Even though this variant generates a 278 novel NxS/T sequon, augmentation of glycan attachment onto the amino acid 279 substitution encoded by the minor allele has not been demonstrated. Structural studies 280 indicate that the variant does not interrupt the kinase domain nor any residues known to 281 be post-translationally modified, glycosylation or otherwise [31,36]. Therefore, the

It is made available under a CC-BY 4.0 International license .

18

impact of the K829N substitution encoded by *rs3809973* on ALPK2 structure and
function warrant investigation.

284	Although the low minor allele frequency of the remaining 6 nsSNV associated with
285	increased liver fibrosis (i.e., CCR7 rs2228015, GLT8D2 rs17035120, MAN2A2
286	rs52828316, <i>MBL2</i> rs1800450, <i>MCOLN2</i> rs77452813, and <i>TGFB1</i> rs1800472)
287	precluded detailed modeling, their previous associations with liver disease, metabolism,
288	and viral immunity in other literature provide impetus for further investigation. TGFB1
289	has long been linked to enhanced hepatocyte destruction and HSC activation [37].
290	GLT8D2 and MAN2A2 have been implicated in non-alcoholic fatty liver disease [38] and
291	coinfected liver disease [39], respectively. Finally, CCR7, MBL2, and MCOLN2 have all
292	been connected to the modulation of host cellular and immune responses in viral
293	infection [40-42]. Taken together, all seven nsSNV and their cognate genes have
294	plausible roles in liver disease pathology and warrant replication in an independent
295	sample(s).

We note that there are limitations to this study. As this is an exclusively female cohort, future studies should aim to validate these findings in men. Although we identified that there are potentially more than 42,000 nsSNV that either directly altered N-linked glycosylation sites (NxS/T) or that may indirectly alter the function of enzymes or lectins interacting with glycoproteins, only a subset (2.5%) were available for analysis in the cohort due to a combination of low nsSNV allele frequency in the population and/or lack of inclusion of the majority of nsSNV on the commercial array used. A number of factors

19

303 hindered our attempts at a longitudinal assessment of the genetic risk factors on the 304 coinfected population. For one, as the standard of care for HIV treatment changed for 305 coinfected WIHS participants longitudinally (Supplemental Figure 2A, 2B), adjusting for 306 shifting antiviral treatment regimens at different time points to meet this standard of care 307 was a challenge. Secondly, as this cohort was initially designed to investigate HIV 308 progression, the HCV virologic status was only determined at baseline and HCV 309 clearance was not assessed further, thereby making longitudinal analyses of HCV-310 infection status susceptible to misclassification bias. Along similar lines, survival bias 311 and the availability of more effective and less toxic HIV treatments for new enrollees 312 over time in WIHS may have attenuated the relationship between susceptibility alleles 313 and fibrosis [27]. The rate of loss to follow-up was also problematic in that nearly one 314 third of the coinfected participants at baseline were no longer in the cohort after four 315 visits (2 years) (Supplemental Figure 2C, 2D). Finally, APRI and FIB-4 scores are 316 correlated with liver fibrosis risk, but both are imperfect surrogate measures. The utility 317 of these surrogate fibrosis metrics has been validated against biopsy and other 318 measures (i.e. transient elastography) in previous studies [43], but were not validated by 319 such methods at present.

Given the goal of improving the prognosis of liver disease in the HIV/HCV coinfected population, we have identified candidate genes that may participate in hepatic fibrosis. Although these genetic associations require replication, demonstration of the impact of each of the seven nsSNVs on N-linked glycosylation of the site and its cognate protein warrants investigation. Longitudinal HCV testing and assessment of viremia along with

It is made available under a CC-BY 4.0 International license .

additional studies in other HIV/HCV coinfected cohorts may permit better stratification of
 serogroups and to perform longitudinal analysis of these candidate gene nsSNV.

ACKNOWLEDGEMENTS

Data in this manuscript were collected by the Women's Interagency HIV Study, now the MACS/WIHS Combined Cohort Study (MWCCS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). MWCCS (Principal Investigators): Atlanta CRS (Ighovwerha Ofotokun, Anandi Sheth, and Gina Wingood), U01-HL146241; Bronx CRS (Kathryn Anastos and Anjali Sharma), U01-HL146204; Brooklyn CRS (Deborah Gustafson and Tracey Wilson), U01-HL146202; Data Analysis and Coordination Center (Gypsyamber D'Souza, Stephen Gange and Elizabeth Golub), U01-HL146193; Chicago-Cook County CRS (Mardge Cohen and Audrey French), U01-HL146245; Connie Wofsy Women's HIV Study, Northern California CRS (Bradley Aouizerat and Phyllis Tien), U01-HL146242; Metropolitan Washington CRS (Seble Kassaye and Daniel Merenstein), U01-HL146205; Miami CRS (Maria Alcaide, Margaret Fischl, and Deborah Jones), U01-HL146203; UAB-MS CRS (Mirjam-Colette Kempf and Deborah Konkle-Parker), U01-HL146192; UNC CRS (Adaora Adimora), U01-HL146194. The MWCCS is funded primarily by the National Heart, Lung, and Blood Institute (NHLBI), with additional co-funding from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Human Genome Research Institute (NHGRI), National Institute On Aging (NIA), National Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Allergy And Infectious Diseases (NIAID),

National Institute Of Neurological Disorders And Stroke (NINDS), National Institute Of Mental Health (NIMH), National Institute On Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). MWCCS data collection is also supported by UL1-TR000004 (UCSF CTSA), P30-AI-050409 (Atlanta CFAR), P30-AI-050410 (UNC CFAR), and P30-AI-027767 (UAB CFAR). Additionally, the authors would like to thank Jing Wu and Yiwen Wang for their data assembly and analysis efforts.

REFERENCES:

- Sherman KE, Peters MG, Thomas D. Human immunodeficiency virus and liver disease: A comprehensive update. *Hepatol Commun.* 2017;1(10):987-1001. doi:<u>10.1002/hep4.1112</u>
- Cahill S, Valadéz R. Growing older with HIV/AIDS: new public health challenges.
 Am J Public Health. 2013;103(3):e7-e15. doi:10.2105/AJPH.2012.301161
- Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir Immune Defic Syndr*. 2006;43(1):27-34. doi:10.1097/01.gai.0000233310.90484.16
- Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol.* 2005;42(6):799-805. doi:<u>10.1016/j.jhep.2005.01.022</u>

5. Avihingsanon A, Jitmitraparp S, Tangkijvanich P, et al. Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. *J Gastroenterol Hepatol*. 2014;29(9):1706-

1714. doi:<u>10.1111/jgh.12613</u>

- Chrysanthidis T, Loli G, Metallidis S, Germanidis G. Mechanisms of accelerated liver fibrosis in HIV-HCV coinfection. *AIDS Rev.* 2017;19(3):148-155.
- Lledó GM, Carrasco I, Benítez-Gutiérrez LM, et al. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. *AIDS*. 2018;32(16):2347-2352.

doi:10.1097/QAD.000000000001966

- Henry B. Drug Pricing & Challenges to Hepatitis C Treatment Access. J Health Biomed Law. 2018;14:265-283.
- Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. *Curr Opin Struct Biol.* 2011;21(5):576-582. doi:10.1016/j.sbi.2011.08.005
- 10. Rudd PM. Glycosylation and the Immune System. *Science*. 2001;291(5512):2370-2376. doi:<u>10.1126/science.291.5512.2370</u>
- 11. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. *Nat Rev Immunol.* 2007;7(4):255-266. doi:<u>10.1038/nri2056</u>
- 12. Van Breedam W, Pöhlmann S, Favoreel HW, de Groot RJ, Nauwynck HJ. Bittersweet symphony: glycan-lectin interactions in virus biology. *FEMS Microbiol Rev.* 2014;38(4):598-632. doi:10.1111/1574-6976.12052

- 13. Mazumder R, Morampudi KS, Motwani M, Vasudevan S, Goldman R. Proteome-Wide Analysis of Single-Nucleotide Variations in the N-Glycosylation Sequon of Human Genes. Dalby AR, ed. *PLoS ONE*. 2012;7(5):e36212. doi:10.1371/journal.pone.0036212
- 14. Fan Y, Hu Y, Yan C, et al. Loss and gain of N-linked glycosylation sequons due to single-nucleotide variation in cancer. Sci Rep. 2018;8(1):4322.

E Racon MC yon Wully Aldon C at al. The Wom

doi:10.1038/s41598-018-22345-2

- 15. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. *Clin Diagn Lab Immunol.* 2005;12(9):1013-1019. doi:<u>10.1128/CDLI.12.9.1013-1019.2005</u>
- 16. Sarkar M, Aouzierat B, Bacchetti P, et al. Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCVcoinfected women. J Viral Hepat. 2015;22(12):1055-1060. doi:<u>10.1111/jvh.12431</u>
- 17. French AL, Martin JW, Evans CT, et al. Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study. *J Acquir Immune Defic Syndr*. 2017;76(4):438-444. doi:10.1097/QAI.00000000001524
- 18. Urabe Y, Ochi H, Kato N, et al. A genome-wide association study of HCVinduced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. *J Hepatol.* 2013;58(5):875-882.

doi:10.1016/j.jhep.2012.12.024

19. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006;43(6):1317-1325. doi:10.1002/hep.21178

20. Lin Z-H, Xin Y-N, Dong Q-J, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology*. 2011;53(3):726-736.

doi:10.1002/hep.24105

- 21. Kuniholm MH, Gao X, Xue X, et al. The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. *J Infect Dis.* 2011;203(12):1807-1814. doi:<u>10.1093/infdis/jir192</u>
- 22. Hansen L, Lind-Thomsen A, Joshi HJ, et al. A glycogene mutation map for discovery of diseases of glycosylation. *Glycobiology*. 2015;25(2):211-224. doi:10.1093/glycob/cwu104
- 23. Bouwman LH, Roos A, Terpstra OT, et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. *Gastroenterology*. 2005;129(2):408-414. doi:10.1016/j.gastro.2005.06.049
- 24. Shendre A, Wiener HW, Irvin MR, et al. Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS). *PLoS ONE*. 2017;12(12):e0188725. doi:<u>10.1371/journal.pone.0188725</u>
- 25. Frasco MA, Mack WJ, Van Den Berg D, et al. Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine. *AIDS*. 2012;26(16):2097-2106. doi:10.1097/QAD.0b013e3283593602

- 26. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. *Gut.* 2003;52(7):1035-1040. doi:<u>10.1136/gut.52.7.1035</u>
- 27. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. *J Hepatol.* 2006;44(1):47-55. doi:10.1016/j.jhep.2005.07.006
- 28. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. *Gut.* 2015;64(5):830-841. doi:<u>10.1136/gutjnl-2014-306842</u>
- 29. O'Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. *World J Gastroenterol.* 2018;24(39):4436-4447. doi:<u>10.3748/wjg.v24.i39.4436</u>
- 30. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. *Nat Rev Gastroenterol Hepatol.* 2017;14(7):397-411. doi:<u>10.1038/nrgastro.2017.38</u>
- 31. Ryazanov AG, Pavur KS, Dorovkov MV. Alpha-kinases: a new class of protein kinases with a novel catalytic domain. *Curr Biol*. 1999;9(2):R43-45.

doi:<u>10.1016/s0960-9822(99)80006-2</u>

- 32. Yoshida Y, Tsunoda T, Doi K, et al. ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. *Anticancer Res.* 2012;32(6):2301-2308.
- 33. Yu LC-H, Wang J-T, Wei S-C, Ni Y-H. Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. World J Gastrointest Pathophysiol. 2012;3(1):27-43. doi:<u>10.4291/wjgp.v3.i1.27</u>

- 34. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med.* 2006;12(12):1365-1371. doi:<u>10.1038/nm1511</u>
- 35. Palmieri O, Creanza TM, Bossa F, et al. Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2015;21(6):1260-1268.

doi:10.1097/MIB.000000000000370

- 36. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. *Nucleic Acids Res*. 2015;43(Database issue):D512-520. doi:<u>10.1093/nar/gku1267</u>
- 37. Dooley S, ten Dijke P. TGF-β in progression of liver disease. *Cell Tissue Res.* 2012;347(1):245-256. doi:<u>10.1007/s00441-011-1246-y</u>
- 38. Zhan Y, Zhao F, Xie P, et al. Mechanism of the effect of glycosyltransferase GLT8D2 on fatty liver. *Lipids Health Dis.* 2015;14:43. doi:<u>10.1186/s12944-015-</u> <u>0040-3</u>
- 39. Gupta P, Liu B, Wu JQ, et al. Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection. *Virology*. 2014;450-451:336-349.

doi:10.1016/j.virol.2013.12.026

40. Hayasaka H, Kobayashi D, Yoshimura H, Nakayama EE, Shioda T, Miyasaka M. The HIV-1 Gp120/CXCR4 axis promotes CCR7 ligand-dependent CD4 T cell migration: CCR7 homo- and CCR7/CXCR4 hetero-oligomer formation as a

possible mechanism for up-regulation of functional CCR7. *PLoS ONE*.

2015;10(2):e0117454. doi:10.1371/journal.pone.0117454

- 41. Eisen S, Dzwonek A, Klein NJ. Mannose-binding lectin in HIV infection. *Future Virol.* 2008;3(3):225-233. doi:10.2217/17460794.3.3.225
- 42. Rinkenberger N, Schoggins JW. Mucolipin-2 Cation Channel Increases

Trafficking Efficiency of Endocytosed Viruses. *mBio.* 2018;9(1).

doi:10.1128/mBio.02314-17

43. Papadopoulos N, Vasileiadi S, Papavdi M, et al. Liver fibrosis staging with

combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an

alternative to transient elastography. Ann Gastroenterol. 2019;32(5):498-503.

doi:10.20524/aog.2019.0406

Author names in **bold** designate shared co-first authorship.


SUPPLEMENTAL FIGURES AND FIGURE LEGENDS:


Supplemental Figure 1. Genotyping and data processing workflow.

Supplemental Figure 2. Longitudinal trends characterizing the HIV/HCV coinfected population: The values are summarized annually at every second visit. (A) Composition of the anti-HIV drug regimens changing in line with treatment guidelines; no therapy (red), monotherapy (blue), combination therapy (green), or highly active antiretroviral therapy (HAART) (purple). (B) Mean CD4⁺ percentages (black symbols) and mean HIV viral load (red symbols). (C) The median APRI and (D) FIB-4 indexes.

It is made available under a CC-BY 4.0 International license .

Supplemental Figure 1. Genotyping and data processing workflow





Supplementary Figure 2. Longitudinal trends characterizing the HIV/HCV coinfected population